Compare Mattel Inc (MAT) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Mattel Inc vs State Street SPDR S&P Biotech ETF — how do they compare? Mattel Inc trades at $16.56 (market cap $4.74B), while State Street SPDR S&P Biotech ETF trades at $149.89 (market cap $10.11B). The key difference: State Street SPDR S&P Biotech ETF is far larger — about 2.1× Mattel Inc's market cap, and State Street SPDR S&P Biotech ETF is trading nearer its 52-week high, Mattel Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Mattel Inc for 97 Days and State Street SPDR S&P Biotech ETF for 37 Days on average.
| MAT | XBI | |
|---|---|---|
Market Cap | $4.74B | $10.11B |
Volume | 11,809,722 | 12,903,266 |
Sector | Consumer Cyclical | Broad Market / Factor |
52-Week High | $22.16 | $169.55 |
52-Week Low | $12.66 | $104.99 |
Typical Hold Time | 97 Days | 37 Days |
Enterprise Value | $6.96B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Mattel (MAT) trades at $16.37, up 2.76% on the day, with a bullish technical signal and strong profitability metrics including a 20.5% ROE and 7.78% net margin. Recent news highlights takeover interest from Authentic Brands Group and a CEO transition to Roger Lynch. Cash flow turned negative in 2025 at -$145M, but revenue remains stable around $5.3B.
The stock presents a mixed outlook: analyst consensus is a Buy with a $15.00 price target, but recent earnings misses and negative cash flow pose risks. Upside is supported by takeover speculation and solid brand portfolio, while execution under new leadership and Barbie sales trends are key watchpoints.
XBI trades at $150.23, down 0.44% on the day, with a bearish technical signal driven by moving averages and oscillators. The ETF's modified equal-weight structure provides exposure to over 150 biotech companies, benefiting from M&A activity and positive clinical catalysts. Recent news highlights sector optimism from cancer vaccine breakthroughs and improved capital access, though the ETF carries higher volatility than broader healthcare funds.
The outlook is mixed: strong sector tailwinds from innovation and consolidation support growth potential, but high volatility and expense ratios relative to peers pose risks. Analyst sentiment is neutral with 100% hold ratings, suggesting cautious optimism amid technical bearishness.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Mattel Inc
Mattel markets toy products that are sold to its wholesale customers and direct to retail consumers. The company offers products for children and families, including toys for infants and preschoolers, girls and boys, youth electronics, handheld and other games, puzzles, educational toys, media-driven products, and plush and fashion-related toys. Mattel's owned portfolio includes Barbie, Hot Wheels, Fisher-Price, Thomas & Friends, and American Girl. In addition, it currently manufactures toy products for its segments both internally and externally (through manufacturing partners). Just over half of its net sales are in North America, while the remainder stem from international markets.
Read more on MAT →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
